🚀 VC round data is live in beta, check it out!
Novonesis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Novonesis and similar public comparables like Sika, Qnity Electronics, Dow, Qinghai Salt Lake Industry and more.
Novonesis Overview
About Novonesis
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
Founded
2000
HQ
Employees
11.6K
Website
Sectors
Financials (LTM)
EV
$31B
Novonesis Financials
Novonesis reported last 12-month revenue of $5B and EBITDA of $2B.
In the same LTM period, Novonesis generated $2B in gross profit, $2B in EBITDA, and $736M in net income.
Revenue (LTM)
Novonesis P&L
In the most recent fiscal year, Novonesis reported revenue of $5B and EBITDA of $2B.
Novonesis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5B | XXX | $5B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 48% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | $2B | XXX | $2B | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 37% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $736M | XXX | $689M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 14% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Novonesis Stock Performance
Novonesis has current market cap of $28B, and enterprise value of $31B.
Market Cap Evolution
Novonesis' stock price is $59.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $31B | $28B | -0.9% | XXX | XXX | XXX | $1.48 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNovonesis Valuation Multiples
Novonesis trades at 6.2x EV/Revenue multiple, and 16.7x EV/EBITDA.
EV / Revenue (LTM)
Novonesis Financial Valuation Multiples
As of April 14, 2026, Novonesis has market cap of $28B and EV of $31B.
Equity research analysts estimate Novonesis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Novonesis has a P/E ratio of 37.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28B | XXX | $28B | XXX | XXX | XXX |
| EV (current) | $31B | XXX | $31B | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBITDA | 16.7x | XXX | 17.0x | XXX | XXX | XXX |
| EV/EBIT | 26.5x | XXX | 27.7x | XXX | XXX | XXX |
| EV/Gross Profit | 13.1x | XXX | 11.8x | XXX | XXX | XXX |
| P/E | 37.7x | XXX | 40.3x | XXX | XXX | XXX |
| EV/FCF | 36.1x | XXX | 35.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Novonesis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Novonesis Margins & Growth Rates
Novonesis' revenue in the last 12 month grew by 6%.
Novonesis' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Novonesis' rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Novonesis' rule of X is 55% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Novonesis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 37% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 44% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 55% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 11% | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 32% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Novonesis Public Comps
See public comps and valuation multiples for other Agriculture and Chemicals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Novonesis | XXX | XXX | XXX | XXX | XXX | XXX |
| Sika | XXX | XXX | XXX | XXX | XXX | XXX |
| Qnity Electronics | XXX | XXX | XXX | XXX | XXX | XXX |
| Dow | XXX | XXX | XXX | XXX | XXX | XXX |
| Qinghai Salt Lake Industry | XXX | XXX | XXX | XXX | XXX | XXX |
| PPG | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Novonesis M&A Activity
Novonesis acquired XXX companies to date.
Last acquisition by Novonesis was on XXXXXXXX, XXXXX. Novonesis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Novonesis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNovonesis Investment Activity
Novonesis invested in XXX companies to date.
Novonesis made its latest investment on XXXXXXXX, XXXXX. Novonesis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Novonesis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Novonesis
| When was Novonesis founded? | Novonesis was founded in 2000. |
| Where is Novonesis headquartered? | Novonesis is headquartered in Denmark. |
| How many employees does Novonesis have? | As of today, Novonesis has over 11K employees. |
| Who is the CEO of Novonesis? | Novonesis' CEO is Ester Baiget. |
| Is Novonesis publicly listed? | Yes, Novonesis is a public company listed on Nasdaq Copenhagen. |
| What is the stock symbol of Novonesis? | Novonesis trades under NSIS B ticker. |
| When did Novonesis go public? | Novonesis went public in 2000. |
| Who are competitors of Novonesis? | Novonesis main competitors are Sika, Qnity Electronics, Dow, Qinghai Salt Lake Industry. |
| What is the current market cap of Novonesis? | Novonesis' current market cap is $28B. |
| What is the current revenue of Novonesis? | Novonesis' last 12 months revenue is $5B. |
| What is the current revenue growth of Novonesis? | Novonesis revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Novonesis? | Current revenue multiple of Novonesis is 6.2x. |
| Is Novonesis profitable? | Yes, Novonesis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Novonesis? | Novonesis' last 12 months EBITDA is $2B. |
| What is Novonesis' EBITDA margin? | Novonesis' last 12 months EBITDA margin is 37%. |
| What is the current EV/EBITDA multiple of Novonesis? | Current EBITDA multiple of Novonesis is 16.7x. |
| What is the current FCF of Novonesis? | Novonesis' last 12 months FCF is $859M. |
| What is Novonesis' FCF margin? | Novonesis' last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Novonesis? | Current FCF multiple of Novonesis is 36.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.